Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non ...

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

Galapagos announces leadership transition. European biotechnology company Galapagos completed a significant leadership ...

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

Muscarinic M4 receptor positive allosteric modulators are detailed in an Acadia Pharmaceuticals Inc. patent. They are reported to be useful for the treatment of Alzheimer’s disease, pain, ...

ACADIA Pharmaceuticals saw its IBD SmartSelect Composite Rating jump to 96 Thursday, up from 94 the day before.

In the preceding three months, 13 analysts have released ratings for ACADIA Pharmaceuticals ACAD, presenting a wide array of ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to ...

The insomnia therapeutics market size has shown steadfast growth in recent years. From a market value of $3.03 billion in 2024, it is projected to grow to $3.21 billion in 2025, demonstrating a ...

Acadia Pharmaceuticals has scored a second court win in less than a month that protects patents for its Parkinson's Disease treatment Nuplazid. The biopharmaceutical company said Monday that a federal ...

Return on Equity (ROE): ACADIA Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 2.53%, the company demonstrates effective use of equity capital and strong ...